89BIO (ETNB)
(Delayed Data from NSDQ)
$8.86 USD
+0.39 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.85 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
89BIO (ETNB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.33 | $53.00 | $12.00 | 269.89% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for 89BIO comes to $31.33. The forecasts range from a low of $12.00 to a high of $53.00. The average price target represents an increase of 269.89% from the last closing price of $8.47.
Analyst Price Targets (9 )
Broker Rating
89BIO currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, eight are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ETNB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
6/12/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
6/11/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
5/17/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
3/6/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
1/19/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
10/12/2023 | UBS | Eliana Merle | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 10 |
Average Target Price | $31.33 |
LT Growth Rate | 8.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.54 |